Pub Date : 2024-07-01DOI: 10.2174/138955752413240417223929
Diego Dal Ben
{"title":"Meet the Frontier Section Editor","authors":"Diego Dal Ben","doi":"10.2174/138955752413240417223929","DOIUrl":"https://doi.org/10.2174/138955752413240417223929","url":null,"abstract":"","PeriodicalId":18717,"journal":{"name":"Mini-reviews in Medicinal Chemistry","volume":"42 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141716588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-12DOI: 10.2174/0113895575316229240611113946
A. Rabie
Finding the most perfect drug candidates in the fields of drug discovery and medicinal chemistry will remain the main interest of drug designers. This concern necessitates organic and medicinal chemists, in most examples, to precisely design and search for drug candidates that are very analogous to the present effective drugs for solving, mainly, their proven critical pharmacological and clinical issues through slightly changing one or two atoms of the principal functional skeletons of the molecules of present therapeutics by atom swapping, removal, and/or addition procedures in organic chemical synthesis. This accurate modern chemicosimilarity tactic in drug discovery surely saves time while keeping us very close, or sometimes highly superior, to the parent pharmacophoric bioactivity (i.e., keeping considerable analogy to the parent therapeutic molecule). From this perspective and logic, the science of skeletal editing of molecules (i.e., skeletal molecular editing) arose in the era of artificial intelligence (AI) and its dramatic predictions. As a pioneer in this modern branch in pharmaceutical and therapeutic organic chemistry, in this up-to-date minireview and perspective article, an attempt was made to introduce skeletal editing and its synthetic surgeries (over molecules) to the audience (including irrelevant readers) in a simpler and more attractive way as a novel chemical technology, highlighting the previous synthetic trials (in general), demonstrating the three main techniques, and, finally, discussing the future therapeutic needs and scenarios from a medicinal chemist's viewpoint.
{"title":"Revolutionizing Playing with Skeleton Atoms: Molecular Editing Surgery in Medicinal Chemistry","authors":"A. Rabie","doi":"10.2174/0113895575316229240611113946","DOIUrl":"https://doi.org/10.2174/0113895575316229240611113946","url":null,"abstract":"\u0000\u0000Finding the most perfect drug candidates in the fields of drug discovery and medicinal\u0000chemistry will remain the main interest of drug designers. This concern necessitates organic and\u0000medicinal chemists, in most examples, to precisely design and search for drug candidates that are\u0000very analogous to the present effective drugs for solving, mainly, their proven critical pharmacological\u0000and clinical issues through slightly changing one or two atoms of the principal functional skeletons\u0000of the molecules of present therapeutics by atom swapping, removal, and/or addition procedures\u0000in organic chemical synthesis. This accurate modern chemicosimilarity tactic in drug discovery\u0000surely saves time while keeping us very close, or sometimes highly superior, to the parent pharmacophoric\u0000bioactivity (i.e., keeping considerable analogy to the parent therapeutic molecule). From\u0000this perspective and logic, the science of skeletal editing of molecules (i.e., skeletal molecular editing)\u0000arose in the era of artificial intelligence (AI) and its dramatic predictions. As a pioneer in this\u0000modern branch in pharmaceutical and therapeutic organic chemistry, in this up-to-date minireview\u0000and perspective article, an attempt was made to introduce skeletal editing and its synthetic surgeries\u0000(over molecules) to the audience (including irrelevant readers) in a simpler and more attractive way\u0000as a novel chemical technology, highlighting the previous synthetic trials (in general), demonstrating\u0000the three main techniques, and, finally, discussing the future therapeutic needs and scenarios\u0000from a medicinal chemist's viewpoint.\u0000","PeriodicalId":18717,"journal":{"name":"Mini-reviews in Medicinal Chemistry","volume":"92 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141352556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.2174/138955752411240402134719
Igor José dos Santos Nascimento, R. D. de Moura
{"title":"Molecular Dynamics Simulations in Drug Discovery","authors":"Igor José dos Santos Nascimento, R. D. de Moura","doi":"10.2174/138955752411240402134719","DOIUrl":"https://doi.org/10.2174/138955752411240402134719","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":18717,"journal":{"name":"Mini-reviews in Medicinal Chemistry","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.2174/138955752319230901160745
Francesco Paolo Busardò
{"title":"Meet the Section Editor","authors":"Francesco Paolo Busardò","doi":"10.2174/138955752319230901160745","DOIUrl":"https://doi.org/10.2174/138955752319230901160745","url":null,"abstract":"","PeriodicalId":18717,"journal":{"name":"Mini-reviews in Medicinal Chemistry","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135170467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Diabetes is one of the important and growing diseases in the world. Among the most common diabetic complications are renal adverse effects. The use of apigenin may prevent the development and progression of diabetes-related injuries. The current study aims to review the effects of apigenin in the treatment of diabetic nephropathy. Methods: In this review, a systematic search was performed based on PRISMA guidelines for obtaining all relevant studies on “the effects of apigenin against diabetic nephropathy” in various electronic databases up to September 2022. Ninety-one articles were obtained and screened in accordance with the predefined inclusion and exclusion criteria. Seven eligible articles were finally included in this review. Results: The experimental findings revealed that hyperglycemia led to the decreased cell viability of kidney cells and body weight loss and an increased kidney weight of rats; however, apigenin administration had a reverse effect on these evaluated parameters. It was also found that hyperglycemia could induce alterations in the biochemical and renal function-related parameters as well as histopathological injuries in kidney cells or tissue; in contrast, the apigenin administration could ameliorate the hyperglycemia-induced renal adverse effects. Conclusion: The results indicated that the use of apigenin could mitigate diabetes-induced renal adverse effects, mainly through its antioxidant, anti-apoptotic, and anti-inflammatory activities. Since the findings of this study are based on experimental studies, suggesting the use of apigenin (as a nephroprotective agent) against diabetic nephropathy requires further clinical studies.
{"title":"The Effects of Apigenin in the Treatment of Diabetic Nephropathy: A Systematic Review of Non-clinical Studies","authors":"Thikra Majid Muhammed, Abduladheem Turki Jalil, Waam Mohammed Taher, Zafar Aminov, Fahad Alsaikhan, Andrés Alexis Ramírez-Coronel, Pushpamala Ramaiah, Bagher Farhood","doi":"10.2174/1389557523666230811092423","DOIUrl":"https://doi.org/10.2174/1389557523666230811092423","url":null,"abstract":"Purpose: Diabetes is one of the important and growing diseases in the world. Among the most common diabetic complications are renal adverse effects. The use of apigenin may prevent the development and progression of diabetes-related injuries. The current study aims to review the effects of apigenin in the treatment of diabetic nephropathy. Methods: In this review, a systematic search was performed based on PRISMA guidelines for obtaining all relevant studies on “the effects of apigenin against diabetic nephropathy” in various electronic databases up to September 2022. Ninety-one articles were obtained and screened in accordance with the predefined inclusion and exclusion criteria. Seven eligible articles were finally included in this review. Results: The experimental findings revealed that hyperglycemia led to the decreased cell viability of kidney cells and body weight loss and an increased kidney weight of rats; however, apigenin administration had a reverse effect on these evaluated parameters. It was also found that hyperglycemia could induce alterations in the biochemical and renal function-related parameters as well as histopathological injuries in kidney cells or tissue; in contrast, the apigenin administration could ameliorate the hyperglycemia-induced renal adverse effects. Conclusion: The results indicated that the use of apigenin could mitigate diabetes-induced renal adverse effects, mainly through its antioxidant, anti-apoptotic, and anti-inflammatory activities. Since the findings of this study are based on experimental studies, suggesting the use of apigenin (as a nephroprotective agent) against diabetic nephropathy requires further clinical studies.","PeriodicalId":18717,"journal":{"name":"Mini-reviews in Medicinal Chemistry","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135786595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：